PharVision Advisers’s Enovis ENOV Stock Holding History

PharVision Advisers’s Portfolio ENOV Stock Details ENOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,975	Closed	-$267K	–	312
2025 Q1	$267K	Buy	+6,975	New	+$296K	0.37%	120

Other funds holding ENOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

DAM

Dorsey Asset Management Chicago, Illinois $1.26B AUM 18.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

PharVision Advisers's ENOV Position: Q2 2025 in Review

PharVision Advisers sold out of Enovis (ENOV) in Q2 2025, closing a stake of 6,975 shares — an estimated $267K sold.

PharVision Advisers first reported a position in ENOV in Q1 2025 and held it in 1 quarter. The position peaked at $267K in Q1 2025. 285 funds tracked by Wall St. Rank hold ENOV as of Q2 2025.

PharVision Advisers reported no remaining Enovis position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 6,975 Enovis shares in Q2 2025, an estimated $267K.
PharVision Advisers first reported a position in Enovis in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Enovis position peaked at $267K in Q1 2025.
285 funds tracked by Wall St. Rank held Enovis as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.